Skip to main content
. 2017 Aug 1;318(5):443–452. doi: 10.1001/jama.2017.9644

Table 3. Adverse Events.

Events No./Total (%)
First-Line Contact Aspiration
(n = 192)
First-Line Stent Retriever
(n = 189)
All-cause mortality at 3 mo 35/181 (19.3) 35/182 (19.2)
Intracranial hemorrhage at 24 ha,b 87/188 (46.3) 85/188 (46.2)
Hemorrhagic infarction 58/188 (30.9) 49/188 (26.6)
Type 1c 23/188 (12.2) 24/188 (13.0)
Type 2d 35/188 (18.6) 25/188 (13.6)
Parenchymal hematoma 24/188 (12.8) 33/188 (17.4)
Type 1e 17/188 (9.0) 19/188 (10.3)
Type 2f 7/188 (3.7) 14/188 (7.6)
Intraventricular hemorrhage 6/188 (3.2) 2/184 (1.1)
Remote intracranial hemorrhage 1/188 (0.5) 1/184 (0.5)
Symptomatic intracranial hemorrhage at 24 h 10/188 (5.3) 12/188 (6.5)
Procedure-related adverse eventsb 31/192 (16.2) 30/189 (15.9)
Embolization in a new vascular territory 7/192 (3.7) 5/189 (2.7)
Arterial perforation 5/192 (2.6) 3/189 (1.6)
Arterial dissection 5/192 (2.6) 2/189 (1.1)
Vasospasm 5/192 (2.6) 12/189 (6.4)
Subarachnoid hemorrhage 13/188 (6.9) 13/188 (7.1)
New ischemic stroke in a different vascular territory 10/188 (5.3) 16/188 (8.5)
a

Assessed by core laboratory.

b

Patients with multiple events of one type were counted once.

c

Isolated petechiae in infarcted tissue without mass effect.

d

Confluent petechiae in infarcted tissue without mass effect.

e

Hemorrhage in <30% of the infarcted area with mild space-occupying effect.

f

Hemorrhage in >30% of the infarcted area with significant space-occupying effect.